Cyclopharm Ltd represents values of innovation, excellence, and patient care. The company maintains a strong corporate philosophy centered around enhancing the field of nuclear medicine through advanced radiopharmaceutical products and services. Cyclopharm Ltd is committed to delivering reliable diagnostic solutions that enable healthcare professionals to effectively diagnose and monitor various diseases. With a focus on research and development, the company strives to introduce groundbreaking technologies and therapies to improve patient outcomes. As a leader in the nuclear medicine industry, Cyclopharm Ltd continuously aims to provide cutting-edge solutions that contribute to the advancement of medical imaging and patient well-being.

Cyclopharm Ltd is primarily present in Australia, New Zealand, and Canada.

Cyclopharm Ltd, a leading healthcare company, has achieved several significant milestones throughout its journey. The company has successfully developed and launched innovative nuclear medicine technologies, including Technegas, a ventilation imaging agent rapidly adopted by the global medical community. Cyclopharm Ltd has established a strong international presence, with distribution networks spanning across multiple continents, allowing them to provide their life-saving products to patients worldwide. The company's commitment to research and development has yielded groundbreaking advancements in diagnostic imaging, revolutionizing the industry. Cyclopharm Ltd continues to strive for excellence, consistently delivering cutting-edge solutions and improving patient outcomes.

Cyclopharm Ltd is a leading global radiopharmaceutical company. Established in 1988, Cyclopharm focuses on developing and commercializing innovative nuclear medicine products. The company specializes in technetium generators, used for diagnostic imaging procedures, particularly in lung ventilation and perfusion examinations. With a strong commitment to research and development, Cyclopharm has continued to expand its product portfolio and global presence over the years. The company is headquartered in Sydney, Australia, and has a strong track record in delivering advanced solutions for the medical imaging industry. Cyclopharm Ltd has emerged as a trusted name in the field of radiopharmaceuticals, providing cutting-edge diagnostic tools for better patient care.

The main competitors of Cyclopharm Ltd in the market include Progenics Pharmaceuticals, Curium, and Navidea Biopharmaceuticals. These companies also operate in the medical imaging industry and offer products and services that compete with Cyclopharm's offerings.

Cyclopharm Ltd is primarily active in the medical and healthcare industries.

The business model of Cyclopharm Ltd revolves around the development and commercialization of nuclear medicine products. Cyclopharm is a global leader in the manufacture and distribution of Technegas, a diagnostic imaging agent used for the detection of pulmonary embolism. With a focus on nuclear medicine, Cyclopharm carries out research, development, and production activities to offer innovative solutions for physicians and patients in need of accurate diagnoses. By leveraging their expertise in nuclear medicine, Cyclopharm aims to improve medical imaging techniques and contribute to better patient outcomes worldwide.

Cyclopharm hissesinin F/K oranı -11,18.

Cyclopharm KUV 4,70 dir.

Cyclopharm için AlleAktien Kalite Skoru 5/10'dur.

beklenen Cyclopharm cirosu 28,28 Milyon. AUD dir.

beklenen Cyclopharm karı -11,90 Milyon. AUD olarak gerçekleşmiştir.

Cyclopharm Ltd is an Australian medical technology company specializing in X-ray diagnostics. The company offers innovative diagnostic solutions and services for nuclear medicine imaging and therapy planning. The company's main business model focuses on three different divisions: diagnostics, therapy planning, and research. Each division has its own products and services. For diagnostics, Cyclopharm offers Atomlab® Systems, a platform for nuclear medicine imaging that combines PET and SPECT technology. Atomlab® Systems facilitates radiologists and doctors in making critical decisions by providing detailed images of the body to help detect abnormalities and diseases. For therapy planning, Cyclopharm offers Technegas®, a technology that allows for checking lung function and perfusion to support the diagnosis of diseases such as pulmonary embolism. Technegas® is approved by the European Union and the US Food and Drug Administration (FDA) and is considered an important part of clinical practice. In addition, Cyclopharm offers a comprehensive portfolio of radioactive isotopes used in diagnostics and therapy planning. Cyclopharm's research division focuses on developing new diagnostic methods and technologies to improve nuclear medicine imaging and deliver better outcomes for patients. The company collaborates with leading academic institutions and research facilities worldwide to develop innovative diagnostic and treatment options. Cyclopharm is headquartered in Sydney, Australia, and distributes its products and services globally. The company employs approximately 100 employees and is listed on the Australian stock exchange. Cyclopharm's business model is based on offering innovative and high-quality diagnostic solutions tailored to the needs of radiologists, doctors, and patients. By combining PET and SPECT technology, Technegas technology, and an isotope portfolio, Cyclopharm has a unique position in nuclear medicine imaging. The company is also committed to sustainability and strives for environmental compatibility and safety in all aspects of its products and services. It works closely with regulatory authorities to ensure compliance with all relevant regulations and guidelines. Overall, Cyclopharm is a leading provider of diagnostic solutions and services in nuclear medicine imaging. Through innovative technology and a strong focus on research and development, the company will continue to play an important role in the industry and contribute to improving healthcare worldwide.

Cyclopharm, yılda kez dağıtılmak üzere 0,01 AUD tutarında temettü ödemektedir.

Cyclopharm için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Cyclopharm şirketinin ISIN kodu AU000000CYC5’dir.

Cyclopharm için Ticker CYC.AX’dir.

Son 12 ay içerisinde Cyclopharm, 0,01 AUD tutarında bir temettü ödedi. Bu, yaklaşık olarak 0,70 % oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Cyclopharm, tahmini olarak 0,01 AUD tutarında bir temettü ödemesi yapacak.

Cyclopharm şirketinin mevcut temettü verimi 0,70 %.

Cyclopharm dönemsel olarak temettü ödemesi yapar. Bu ödemeler , , , aylarında gerçekleştirilir.

Cyclopharm, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0,01 AUD tutarında temettü ödenmesi beklenmektedir. Bu, 0,65 % oranında bir temettü verimidir.

Cyclopharm, 'Sağlık' sektörüne atanmıştır.

Son Cyclopharm tarihinde 0,005 AUD tutarındaki en son temettüyü alabilmek için, hisseyi tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi olarak gerçekleşti.

2023 yılında Cyclopharm tarafından 0,01 AUD olarak temettüler dağıtıldı.

Cyclopharm hisselerinin temettüleri AUD olarak dağıtılır.